3.25 CD200 and CD148 Expression in B-Cell Non-Hodgkin's Lymphoma

Abstract

B-cell non-Hodgkin's lymphoma (B-NHL) is a diverse group of mature B-cell–derived neoplasms including diffuse large B-cell lymphoma, chronic lymphocytic leukemia (CLL), follicular lymphoma, mantle cell lymphoma (MCL), splenic marginal zone lymphoma (SMZL), hair cell leukemia (HCL), and other mature B-cell lymphomas. Different combinations of biomarkers analyzed by flow cytometry are critical for the precise diagnosis of leukemic-phase B-NHL, among which CD200 and CD148 expression are promising in the differential diagnosis of these confusing B-cell neoplasms. We evaluated the expression patterns, including percentage and mean fluorescence intensity (MFI), of CD200 and CD148 in 168 patients with B-NHL (132 with CLL, 17 with MCL, 12 with SMZL, 5 with CLL and Richter's syndrome, and 2 with HCL) by flow cytometry analysis of fresh peripheral blood or bone marrow samples. Our results indicate that expression patterns of CD200 and CD148 distinguish different B-cell lymphoid neoplasms and may have potential value in the differential diagnosis in B-NHL, especially in CD5-positive B-NHL, CLL, and MCL and other CD5+ mature B-cell neoplasms. The CD200 expression percentages in CLL, MCL, and SMZL were 75.16% ± 18.99%, 20.49% ± 9.78%, and 14.21% ± 24.54%, respectively (Abstract 3.25, Abstract 3.25, Abstract 3.25, Abstract 3.25), and CD200 MFIs in CLL, MCL, and SMZL were 191.81 ± 125.94, 24.55 ± 39.36, and 36.49 ± 95.40 (Abstract 3.25, Abstract 3.25, Abstract 3.25, Abstract 3.25); both CD200 expression percentage and MFI differed significantly among groups (P < 0.0001). In contrast, CD148 expression percentages in CLL, MCL, and SMZL were 71.28% ± 22.17%, 76.13% ± 27.36%, and 56.74% ± 28.58%, respectively, which did not statistically differ among the groups (P > 0.05) (Abstract 3.25, Abstract 3.25, Abstract 3.25, Abstract 3.25); however, CD148 MFIs were 112.33 ± 90.01, 304.75 ± 183.58, and 203.14 ± 299.26, which did significantly differ between CLL and MCL (P < 0.0001) (Abstract 3.25, Abstract 3.25, Abstract 3.25, Abstract 3.25). Expression of CD200 and CD148 in other mature B-cell lymphomas (CLL and Richter's syndrome, lymphoplasmacytic lymphoma, and HCL) also show diverse patterns (Abstract 3.25, Abstract 3.25, Abstract 3.25, Abstract 3.25). We further investigated CD200 and CD148 MFIs for their value in differential diagnosis between CLL and MCL. Receiver-operating characteristic curve (ROC) and area under the ROC curve (AUC) analyses suggested that CD200 MFI yielded an AUC of 0.944 and CD148 MFI yielded an AUC of 0.857 in discriminating CLL from MCL. Our results suggest that expression patterns of CD200 and CD148 differ among B-NHLs; CD200 and CD148 may have potential differential diagnostic value in B-NHL, especially in CLL and MCL, and introduction of CD200 and CD148 MFI could be a powerful addition to the B-cell lymphoproliferative disease diagnostic panel. Abstract 3.25CD200 MFI in B-NHL View Large Image Figure Viewer Abstract 3.25Expression Percentage in B-NHL View Large Image Figure Viewer Abstract 3.25CD148 MFI in B-NHL View Large Image Figure Viewer